JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide ...
https://www.thehindubusinessline.com/markets/aurobindos-subsidiary-secures-approval-for-budesonide-inhalation-suspension/article67589939.ece Copy Aurobindo Pharma ...
Teva announced the launch of Budesonide Inhalation Suspension, the generic version of AstraZeneca‘s Pulmicort Respules. Pulmicort Respules are indicated as maintenance treatment to control and prevent ...
Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic rhinosinusitis with nasal polyps when compared with placebo, according to study results. In a double ...
Research and Markets: Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback